Boston Scientific
| Company type | Public |
|---|---|
| ISIN | US1011371077 |
| Industry | Medical device |
| Founded | June 29, 1979 in Watertown, Massachusetts |
| Founders | |
| Headquarters | Marlborough, Massachusetts, U.S. |
Key people | |
| Revenue | US$16.75 billion (2024) |
| US$2.603 billion (2024) | |
| US$1.853 billion (2024) | |
| Total assets | US$39.39 billion (2024) |
| Total equity | US$21.77 billion (2024) |
Number of employees | 53,000 (2024) |
| Website | bostonscientific |
42°21′37.3″N 71°33′32.6″W / 42.360361°N 71.559056°W Boston Scientific Corporation (BSC), headquartered in Marlborough, Massachusetts and incorporated in Delaware, is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is widely known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM subcutaneous implantable defibrillator (S-ICD).